

Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Information for the public

Published: 16 April 2025

www.nice.org.uk

Rucaparib (Rubraca) is available on the NHS. It is a possible maintenance treatment for advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after a complete or partial response to first-line platinum-based chemotherapy in adults, only if:

- it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or
- it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because:
 - NHS England's BEV3 and BEV10 commissioning approval criteria for having it are not met, or
 - it is contraindicated or not tolerated.

If you are not eligible for rucaparib but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on ovarian cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Ovarian Cancer Action](#), 0207 380 1730
- [Ovacome](#), 0800 008 7054
- [Target Ovarian Cancer](#), 0808 802 6000
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6921-0